, subtype Meningothelial: 23.7% (33/139) Fibrous or fibroblastic: 7.2% (10/139) Transitional or mixed: 15.1% (21/139) Psammomatous: 5.1% (7/139
, Mitosis (/1.6 mm²) (mean ± SEM, range)
,
, CD34 MVD (mean ± SD ; range) 246 ± 103, vol.962, pp.76-1038
, CD105 MVD (mean ± SD ; range) 49 ± 37, vol.379, pp.0-379
, MVP: microvascular proliferation; MVD: microvessel density; NA: not available; SEM: standard error of mean; SD: standard deviation; WHO: World Health Organization
Pathodiagnostic parameters for meningioma grading, J Clin Neurosci, vol.15, pp.1370-1375, 2008. ,
Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients, Neurosurgery, vol.67, pp.1124-1156, 2010. ,
Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis, Surg Neurol, vol.26, pp.461-470, 1986. ,
Part II: A new grading system based on morphological and imaging criteria, J Neurooncol, vol.34, pp.61-78, 1997. ,
Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas, Acta Neuropathol, vol.114, pp.147-56, 2007. ,
Pathology and molecular genetics of meningioma: recent advances, Neurol Med Chir (Tokyo), vol.55, pp.14-27, 2015. ,
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in, Review) Neuro Oncol, vol.14, issue.5, pp.1-49, 2005. ,
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Review) Acta Neuropathol, vol.131, pp.803-823, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01479018
Histological classification and molecular genetics of meningiomas, Review) Lancet Neurol, vol.5, pp.1045-54, 2006. ,
TERT Promoter Mutations and Risk of Recurrence in ,
, Gov't) J Natl Cancer Inst, vol.108, 2016.
Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, Gov't) Science, vol.339, pp.1077-80, 2013. ,
Malignancy" in meningiomas: a clinicopathologic study of 116 patients, with grading implications, Cancer, vol.85, pp.2046-56, 1999. ,
Intracranial meningioma-a population study of ten years, Acta Neurol Scand, vol.46, pp.102-112, 1970. ,
The recurrence of intracranial meningiomas after surgical treatment, J Neurol Neurosurg Psychiatry, vol.20, pp.22-39, 1957. ,
Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. (Evaluation Studies), Int J Radiat Oncol Biol Phys, vol.75, pp.399-406, 2009. ,
,
, Bull Cancer Radiother, vol.82, pp.35-44, 1995.
Relevance of Simpson grading system and recurrence-free survival after surgery for World Health Organization Grade I meningioma, J Neurooncol, vol.18, pp.1-11, 2016. ,
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer, Comparative Study Research Support, vol.30, pp.1031-1035, 2003. ,
Glomeruloid microvascular proliferation is superior to intratumoral microvessel density as a prognostic marker in non-small cell lung cancer, Gov't) Cancer Res, vol.63, pp.6791-6795, 2003. ,
Prominent microvascular proliferation in clinically aggressive neuroblastoma, Gov't) Clin Cancer Res, vol.13, pp.3499-506, 2007. ,
Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. (Comment Review), Am J Pathol, vol.158, pp.789-96, 2001. ,
A rare pattern of angiogenesis in meningiomas: glomeruloid microvascular proliferation, Case Reports) Turk Neurosurg, vol.24, pp.765-774, 2014. ,
Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas, Non-U.S. Gov't) Br J Haematol, vol.140, pp.402-412, 2008. ,
Analysis of endoglin expression in normal brain tissue and in cerebral arteriovenous malformations, Non-U.S. Gov't) Stroke, vol.31, pp.2653-60, 2000. ,
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. (Comparative Study), Hum Pathol, vol.36, pp.955-61, 2005. ,
Endoglin is a better marker than CD31 in evaluation of angiogenesis in glioblastoma, Croat Med J, vol.46, pp.417-439, 2005. ,
Comparative evaluation of microvessel density determined by CD34 or CD105 in benign and malignant gastric lesions. (Comparative Study), Hum Pathol, vol.37, pp.861-867, 2006. ,
Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. (Comparative Study Research Support, Gov't) Neuropathology, vol.25, pp.201-207, 2005. ,
WHO Classification of Tumours of the Central Nervous System, Revised. Fourth Edition, 2016. ,
Increased expression of VEGF-receptors (FLT-1, KDR, NRP-1) and thrombospondin-1 is associated with glomeruloid microvascular proliferation, an aggressive angiogenic phenotype, in malignant melanoma. (Comparative Study Research Support, Gov't) Angiogenesis, vol.6, pp.295-301, 2003. ,
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States, Neuro Oncol, vol.17, pp.1-62, 2008. ,
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma, Extramural) PLoS One, vol.8, pp.281-289, 2013. ,
Predicting outcomes of patients with intracranial meningiomas using molecular markers of hypoxia, vascularity, and proliferation, Gov't) Neurosurgery, vol.71, pp.146-56, 2012. ,
Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches, Gov't) Clin Neuropathol, vol.31, pp.352-60, 2012. ,
Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival, J Neurooncol, vol.82, pp.249-56, 2007. ,
The measurement of observer agreement for categorical data, Biometrics, vol.33, pp.159-74, 1977. ,
Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas, Cancer, vol.79, pp.1381-93, 1997. ,
Prognostic importance of glomeruloid microvascular proliferation indicates an aggressive angiogenic phenotype in human cancers, Cancer Res, vol.62, pp.6808-6819, 2002. ,
Correlations between MR and endothelial hyperplasia in low-grade gliomas, Non-U.S. Gov't) J Magn Reson Imaging, vol.26, pp.52-60, 2007. ,
URL : https://hal.archives-ouvertes.fr/hal-00169038
Pathology concordance levels for meningioma classification and grading in NRG Oncology RTOG Trial 0539, Extramural) Neuro Oncol, vol.18, pp.565-74, 2016. ,
Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma, Gov't) Anticancer Res, vol.34, pp.3431-3439, 2014. ,
CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34, Virchows Arch, vol.463, pp.673-682, 2013. ,
CD105 Over-expression Is Associated with Higher WHO Grades for Gliomas, Mol Neurobiol, vol.53, pp.3503-3515, 2016. ,
Sstr2A immunohistochemical expression in human meningiomas: is there a correlation with the histological grade, proliferation or microvessel density?, Oncol Rep, vol.20, pp.485-92, 2008. ,
Opportunities for clinical research in meningioma, J Neurooncol, vol.99, pp.417-439, 2010. ,
Preoperative particle and glue embolization of meningiomas: indications, results, and lessons learned from 117 consecutive patients, Neurosurgery, vol.73, pp.244-51, 2013. ,
Delayed surgical resection reduces intraoperative blood loss for embolized meningiomas, Neurosurgery, vol.50, pp.1231-1236, 2002. ,
Embolisation of intracranial meningiomas without subsequent surgery. (Comparative Study), Neuroradiology, vol.45, pp.451-456, 2003. ,
New approaches for the treatment of refractory meningiomas, Case Reports) Cancer Control, vol.10, pp.148-58, 2003. ,
Therapeutic embolization of meningiomas with Onyx for delayed surgical resection, Case Reports) Surgical neurology, vol.70, pp.478-81, 2008. ,
Atypical and anaplastic meningiomas treated with bevacizumab, J Neurooncol, vol.109, pp.187-93, 2012. ,
DOI : 10.1007/s11060-012-0886-4
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series, J Neurooncol, vol.109, pp.63-70, 2012. ,
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma, Clin Genitourin Cancer, 2016. ,
A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer. (Clinical Trial, Phase I), BJU Int, vol.116, pp.546-55, 2015. ,
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. (Clinical Trial, Phase I Multicenter Study Research, Gov't) Clin Cancer Res, vol.20, pp.5918-5944, 2014. ,
Glomeruloid microvascular proliferation follows adenoviral vascular permeability factor/vascular endothelial growth factor-164 gene delivery, Am J Pathol, vol.158, pp.1145-60, 2001. ,
Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human meningiomas, Non-U.S. Gov't) J Neurooncol, vol.88, pp.143-55, 2008. ,